Skip to main content
Premium Trial:

Request an Annual Quote

RiNA, Affymetrix, Samsung Electronics, SurModics, 3D Biosurfaces

RiNA of Berlin has received European Patent No. 1763589, "Blueprint biochips." The patent claims a method for producing a surface with one or more products attached by: a) putting a first and second surface in top of each other, where enzymes are attached to distinct sites on the first surface; b) contacting the enzymes with more enzymes enabling generation of more products by the enzymes; and c) attaching the subsequent products to distinct sites in the second surface. According to the patent's abstract, the first surface is a DNA chip or a protein chip.

Affymetrix has received US Patent No. 7,197,400, "System and computer software products for comparative gene expression analysis." The patent claims methods and computer software products for analyzing gene expression data. Methods, systems and computer software are also provided for comparative gene expression analysis using intensity dependent normalization factors as well as for comparing gene expression experiment results using two or more nucleic acid probe arrays.

Samsung Electronics has received US Patent No. 7,195,924, "Method for immobilizing a biomolecule on a solid substrate at a high density by using the substrate having an activated carboxyl group on a surface thereof and microarray produced using the method."The patent claims a method for immobilizing a biomolecule on a solid substrate. The method includes coating the solid substrate with silane anhydride to introduce an anhydride functional group onto a surface of the solid substrate; obtaining a carboxyl group from the anhydride functional group by hydrolysis; reacting the carboxyl group with carbodiimide and succinimide to activate the carboxyl group; and contacting the biomolecule with the solid substrate having the activated carboxyl group on its surface to immobilize the biomolecule on the solid substrate. A microarray is subsequently produced using the claimed method.

SurModics of Eden Prairie, Minn., has received US Patent No. 7,195,913, "Randomly ordered arrays and methods of making and using." The patent claims a method of detecting a target in a sample using an array of probes. The target can be detecting using an array that includes a substrate and a plurality of microparticles which are coupled to probes and randomly immobilized on the substrate. Each microparticle includes a probe and a self-encoding marker which forms a unique self-encoding marker-probe pair on the microparticle, according to the patent. Detection of the target in a sample is accomplished by applying a sample suspected of containing the target to the array, allowing the target to bind to the probes coupled to the microparticles, and then detecting a target marker coupled to the target and detecting the self encoding markers of microparticles having unique self-encoding marker-probe pairs. Although the microparticles are randomly located on at least a portion of the array, the presence and identity of the target can be determined by the self-encoding marker-probe pairs.


3D Biosurfaces of Tucson, Ariz., has received US Patent No. 7,195,872, "High surface area substrates for microarrays and methods to make same." The patent describes a microarray device that includes: a) a substrate with a textured surface that contains microfeatures; and b) a plurality of separate array elements immobilized on two adjacent microfeatures to form a textured array element. The increased surface area of the constructed array is capable of producing an improved uniformity of signal intensity, the patent states.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.